Contain your costs while improving outcomes. Integrative cancer care makes it possible.
When it comes to oncology care, payors face two challenges: managing risk and ensuring better outcomes across the cancer care continuum. We show you how meeting one goal helps achieve the other — and that you don’t have to take on either alone.
Find out how
Broader market access begins with integration.
From launch strategies to adherence programs to outcome reporting, we work with you to reach your goals for your drugs. Our custom solutions enhance patient access, and our care management models encourage patients to stay on therapy. It’s all part of our integrative cancer care approach.
Find out how
For your oncology trial, success is in the details.
Cancer therapeutics are as complex as the diseases they treat, but we can make clinical studies simpler. When you trust us to manage the details, from patient kit logistics and distribution to outcome reporting, you can concentrate on the science. We take care of everything else.
Find out how
We free clinicians to focus on the fight.
We specialize in cancer care alignment, synchronizing services so you and your patients can concentrate on treatment instead of logistics. We’re working on your patient’s behalf at every point in the cancer care continuum — so you know nothing will slip through the cracks.
Find out how
NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting
CARY, N.C. (July 21, 2017) —Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA). NERLYNX is indicated for the extended adjuvant treatment …
Read more
